Yuelei Shen, Ph.D.
President & CEO
Dr. Yuelei Shen is the founder, President and CEO of Beijing Biocytogen Co., LTD. Dr. Shen received his Ph.D from the University of Massachusetts Medical School in 2003. He performed his postdoctoral training under Dr. Dan R. Littman in New York University School of Medicine from 2003-2008. In 2008, Dr. Shen founded Biocytogen in Worcester, MA and in 2009, he moved back to Beijing, China and established Beijing Biocytogen Co., LTD. In 2015, Biocytogen Jiangsu Co., Ltd was established, and in 2018, Biocytogen Boston Corporation began operations in Wakefield, MA. In the past 10 years, Biocytogen has transformed from a business that solely provides custom gene-targeted models to one that offers a comprehensive set of Immuno-Oncology (I/O) and antibody development platforms. These platforms cover innovative animal model generation, large scale production, pharmacology studies and therapeutic antibody discovery services. Our chief goal is to promote drug discovery more efficiently.
Chaoshe Guo, Ph.D., M.D.
Vice President, Global Head of Business Development
Dr. Guo graduated from University of Goettingen & Max-Planck-Institute of Biophysical Chemistry, Germany and received a doctoral degree in Biochemistry in November, 2003, where he worked on the functional study of molecular chaperones via biochemistry, structural biology, and gene knockout mouse models. In 2005-2013, Dr. Guo has focused on cardiovascular and blood system development in Boston Children’s Hospital/Harvard Medical School. His research has been published in JCI, Development, and other highly reputed journals. Dr. Guo is experienced in animal model generation and phenotype analysis. In October, 2013, Dr. Guo served as the Senior R&D Director and Key Account Manager of Beijing Biocytogen Co., Ltd, to help the company establish CRISPR based gene editing platform and marketing promotion, and also got involved in humanized immune checkpoint animal model generation. Since June 2015, Dr. Guo served as the Vice President of Marketing and Global Head of Business Development.
Qingcong Lin, Ph.D.
Senior Vice President of Biocytogen,
CEO of Biocytogen Boston Corporation
Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation, focusing on providing services on gene-targeting and humanized mouse models, using cutting-edge ESC and CRISPR-Cas9 technology for immuno-oncology antibody candidate in vivo efficacy and toxicity assessment. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group. Dr. Lin has extensive expertise in multiple therapeutic areas, including cancer, CVMD, neurology, immunology & inflammation and various technologies, including genetically engineered mouse models, therapeutic antibody engineering, affinity maturation and optimization. Prior to joining Sheongen, Dr. Lin worked at Pfizer as a principal research scientist II and group leader of antibody engineering group. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab of Harvard-Partners Center for Genetics and Genomics. Dr. Lin received Ph.D. from Albert-Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.
Benny Yang, Ph.D.
Chief Scientific Officer & Director of Antibody Discovery
Dr. Yang graduated from Fudan University with a Master’s degree in Microbiology. He received his Ph.D. degree in Immunology from University of Connecticut Health Center (UCHC) and completed his postdoctoral training at New York University School of Medicine in Dr. Dan Littman’s research group. Then Dr. Yang was recruited to the Medical University of South Carolina (MUSC) as a tenure-track Assistant Professor at the Department of Microbiology and Immunology. In 2016, he joined Biocytogen and has been leading the antibody drug discovery.
Lei Chen, Ph.D.
Senior Director of Antibody Discovery
Lei Chen has served as Senior Director of Antibody Discovery at Biocytogen since October, 2019. He brings to Biocytogen a decade of biologics R&D leadership and experience moving protein therapeutics through development for world-renowned large pharmaceutical companies. Dr. Chen joined Biocytogen from Merck Sharp & Dohme, where he most recently served as associate principal scientist, biologics discovery & engineering. Prior to joining Merck, Dr. Chen spent 7 years at Abbott/Abbvie Bioresearch Center. He served as senior scientist of Antibody Discovery & Engineering at Global Biologics, Abbvie.
Dr. Chen holds a Ph.D. in microbiology from the University of Washington at Seattle, WA, USA. After graduation, he had his postdoctoral training with Dr. Andrew Bradbury, a world renowned scientist on protein engineering, at the Los Alamos National Laboratory, Los Alamos, NM, USA.
James Jin, Ph.D.
Vice President of Biocytogen
Dr. James Jin received his PhD of virology at Wuhan University in 1997. He had his postdoctoral training at Colorado State University. He worked as a research assistant professor in University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a senior scientist. Dr. Jin joined Biocytogen as the director of technology in 2011, and then was promoted to vice president in 2012. His research covers virology, immunology, proteomics, protein structure, human stem cell, and gene-targeting animal model.
Yan Zhu, EMBA
Vice President of Operations
Yan Zhu joined Beijing Biocytogen in 2011, and she currently serves as the Vice President of Operations. Ms. Zhu is responsible for the company’s overall operations, such as research and development (R&D), production, services, human resources and general support. Ms. Zhu has more than 10 years of experience in clinical practices; she has been engaged in research and development management, project investment, operation management and sales in the biomedical industry for nearly 20 years. Ms. Zhu holds an EMBA from Tsinghua University and a bachelor’s degree from the Harbin Medical University (both in China).
Haichao Zhang, Ph.D.
Operation Director of Haimen (Jiangsu) Animal Center
Dr. Zhang joined Beijing Biocytogen in 2010. Since 2016, Dr. Zhang has served as the Operation Director of Biocytogen Haimen (Jiangsu) Animal Center. In the past, Dr. Zhang has worked as the Director of Molecular Biology and the Director of Marketing. Dr. Zhang holds a Ph.D. from the China Pharmaceutical University and a bachelor’s degree in Biochemistry from the Hebei Normal University (both in China).
Jiawei Yao, Ph.D.
Director of Gene Editing
Dr. Yao received a bachelor of science in Bioengineering from Tianjin University of Technology, a master’s degree in Biochemtry from the Tianjin University, and holds a Ph.D. in Pharmaceutical Engineering from the Tianjin University. Dr. Yao currently serves as the Director of the Gene Editing who oversees the research and development (R&D) of gene targeting.
Rui Huang, Ph.D.
Senior Director of Preclinical Services
Dr. Huang joined Beijing Biocytogen in 2011. Dr. Huang has successively served as the Director of Technology, Director of Gene Targeting in the past, and she is now the Senior Director of Preclinical Services. Dr. Huang holds a Ph.D. in Biochemistry and Molecular Biology from the Academy of Military Medical Sciences and a bachelor’s degree in science and biological sciences from the College of Life Sciences, Henan Normal University (both in China).
Yanan Guo, Ph.D., M.D.
Director of Preclinical Services
Prior to joining Biocytogen Beijing in 2014 as the Director of Preclinical Services in 2014, Dr. Guo was working as a postdoc researcher in the Department of Translational Medicine, Brigham & Women’s Hospital of Harvard Medical School in the United States. With more than 10 years of research experience in cancer biology and neurobiology, Dr. Guo has an extensive understanding of the signaling pathways in human diseases, high-throughput gene sequencing, automated drug screening, animal model phenotypic analysis, and using animal models for drug efficacy studies. Dr. Guo holds a Ph.D. in Neurobiology/Pharmacology from the University of Rochester (in the United States), and a bachelor’s degree from the Department of Biological Science and Technology of Tsinghua University (in China). In 2015, she was selected as a member of the “Overseas Talent Aggregation Project” in Beijing.